These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 21511051)

  • 1. Targeting survivin in cancer: the cell-signalling perspective.
    Kanwar JR; Kamalapuram SK; Kanwar RK
    Drug Discov Today; 2011 Jun; 16(11-12):485-94. PubMed ID: 21511051
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survivin signaling in clinical oncology: a multifaceted dragon.
    Kanwar JR; Kamalapuram SK; Kanwar RK
    Med Res Rev; 2013 Jul; 33(4):765-89. PubMed ID: 22688671
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treat cancers by targeting survivin: just a dream or future reality?
    Coumar MS; Tsai FY; Kanwar JR; Sarvagalla S; Cheung CH
    Cancer Treat Rev; 2013 Nov; 39(7):802-11. PubMed ID: 23453862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IAP antagonists: promising candidates for cancer therapy.
    Mannhold R; Fulda S; Carosati E
    Drug Discov Today; 2010 Mar; 15(5-6):210-9. PubMed ID: 20096368
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
    Mita AC; Mita MM; Nawrocki ST; Giles FJ
    Clin Cancer Res; 2008 Aug; 14(16):5000-5. PubMed ID: 18698017
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical aspects for survivin: a crucial molecule for targeting drug-resistant cancers.
    Singh N; Krishnakumar S; Kanwar RK; Cheung CH; Kanwar JR
    Drug Discov Today; 2015 May; 20(5):578-87. PubMed ID: 25433305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting of multiple signalling pathways by heat shock protein 90 molecular chaperone inhibitors.
    Powers MV; Workman P
    Endocr Relat Cancer; 2006 Dec; 13 Suppl 1():S125-35. PubMed ID: 17259553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting survivin in cancer: patent review.
    Kanwar JR; Kamalapuram SK; Kanwar RK
    Expert Opin Ther Pat; 2010 Dec; 20(12):1723-37. PubMed ID: 21083520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting survivin for therapeutic discovery: past, present, and future promises.
    Peery RC; Liu JY; Zhang JT
    Drug Discov Today; 2017 Oct; 22(10):1466-1477. PubMed ID: 28577912
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sorafenib induces apoptotic cell death in human non-small cell lung cancer cells by down-regulating mammalian target of rapamycin (mTOR)-dependent survivin expression.
    Kim YS; Jin HO; Seo SK; Woo SH; Choe TB; An S; Hong SI; Lee SJ; Lee KH; Park IC
    Biochem Pharmacol; 2011 Aug; 82(3):216-26. PubMed ID: 21601561
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is survivin the potential Achilles' heel of cancer?
    Lladser A; Sanhueza C; Kiessling R; Quest AF
    Adv Cancer Res; 2011; 111():1-37. PubMed ID: 21704829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting RAS signalling pathways in cancer therapy.
    Downward J
    Nat Rev Cancer; 2003 Jan; 3(1):11-22. PubMed ID: 12509763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of drug inhibition of signalling molecules.
    Sebolt-Leopold JS; English JM
    Nature; 2006 May; 441(7092):457-62. PubMed ID: 16724058
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibitor of apoptosis proteins as targets for anticancer therapy.
    Fulda S
    Expert Rev Anticancer Ther; 2007 Sep; 7(9):1255-64. PubMed ID: 17892425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanotechnology based platforms for survivin targeted drug discovery.
    Samarasinghe RM; Gibbons J; Kanwar RK; Kanwar JR
    Expert Opin Drug Discov; 2012 Nov; 7(11):1083-92. PubMed ID: 22950742
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key cancer cell signal transduction pathways as therapeutic targets.
    Bianco R; Melisi D; Ciardiello F; Tortora G
    Eur J Cancer; 2006 Feb; 42(3):290-4. PubMed ID: 16376541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Current status of the molecular mechanisms of anticancer drug-induced apoptosis. The contribution of molecular-level analysis to cancer chemotherapy.
    Kim R; Tanabe K; Uchida Y; Emi M; Inoue H; Toge T
    Cancer Chemother Pharmacol; 2002 Nov; 50(5):343-52. PubMed ID: 12439591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Modulation of cell sensitivity to antitumor agents by targeting survival pathways.
    Perego P; Cossa G; Zuco V; Zunino F
    Biochem Pharmacol; 2010 Nov; 80(10):1459-65. PubMed ID: 20688050
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting inhibitor of apoptosis proteins for therapeutic intervention.
    Ndubaku C; Cohen F; Varfolomeev E; Vucic D
    Future Med Chem; 2009 Nov; 1(8):1509-25. PubMed ID: 21426063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 9-Aminoacridine-based anticancer drugs target the PI3K/AKT/mTOR, NF-kappaB and p53 pathways.
    Guo C; Gasparian AV; Zhuang Z; Bosykh DA; Komar AA; Gudkov AV; Gurova KV
    Oncogene; 2009 Feb; 28(8):1151-61. PubMed ID: 19137016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.